| VU-29 |
VU-29 |
890764-36-0 |
| 2-CHLORO-4-(2-FLUOROPYRIDIN-3-YL)PYRIMIDINE(WX150098) |
2-氯-4-(2-氟吡啶-3-基)嘧啶 |
954216-54-7 |
| 4-(bromomethyl)-4'-(trifluoromethyl)-1,1'-biphenyl |
4-(溴甲基)-4'-(三氟甲基)-1,1'-联苯 |
613241-14-8 |
| 4E2RCat |
432499-63-3 |
432499-63-3 |
| 4H-1-Benzothiopyran-4-one, 2,3-dihydro-2-[1-(phenylMethyl)-4-piperidinyl]- |
化合物Σ1 RECEPTOR ANTAGONIST-1 |
1204401-49-9 |
| 6-Bromo-1H-quinoline-2,4-dione |
6-溴-2-羟基喹啉-4(1H)-酮 |
138964-51-9 |
| 2-[2-(3-quinolyl)-4-pyridyl]-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one |
2-[2-(3-quinolyl)-4-pyridyl]-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one |
724711-21-1 |
| (6-amino-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester |
叔丁基((6-氨基吡啶-3 - 基)甲基)氨基甲酸 |
400720-77-6 |
| PF-3450074 |
PF-3450074 |
1352879-65-2 |
| CID 1375606 |
CID-1375606 |
313493-80-0 |
| N-((4-(4-phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide |
N-[[4-(4-PHENYLPIPERAZIN-1-YL)OXAN-4-YL]METHYL]-2-PHENYLSULFANYLPYRIDINE-3-CARBOXAMIDE |
1428327-31-4 |
| N-(2-(diMethylaMino)ethyl)-1-(3-((4-((2-Methyl-1H-indol-5-yl)oxy)pyriMidin-2-yl)aMino)phenyl)MethanesulfonaMide |
5-羟基-2-甲基吲哚 |
1308672-74-3 |
| 2-(AMINOMETHYL)-4-CHLOROANILINE |
2-氨基甲基-4-氯苯胺 |
108047-39-8 |
| Atglistatin |
ATGLISTATIN |
1469924-27-3 |
| BCI-121 |
BCI-121 |
432529-82-3 |
| PLpro inhibitor |
5-(乙酰氨基)-2-甲基-N-[(1R)-1-(1-萘基)乙基]苯甲酰胺 |
1093070-14-4 |
| tert-Butyl 3-(((trifluoroMethyl)sulfonyl)oxy)-2,5-dihydro-1H-pyrrole-1-carboxylate |
3-(三氟甲基磺酰氧基)-2H-吡咯-1(5H)-羧酸叔丁酯 |
630121-86-7 |
| TUG 891 |
TUG 891 |
1374516-07-0 |
| 6-chloro-5-(4-(1-hydroxycyclobutyl)phenyl)-1H-indole-3-carboxylicacid |
PF-06409577 |
1467057-23-3 |
| 4-ACETYLBENZALDEHYDE |
4-乙酰苯甲醛 |
3457-45-2 |
QQ
